Success of the capital increase

VALBIOTIS announces the success of the capital increase with maintenance of the Shareholders’ Preferential Subscription Right, for an amount of 7.2 M€.

Press release

Success of the capital increase

VALBIOTIS announces the success of the capital increase with maintenance of the Shareholders’ Preferential Subscription Right, for an amount of 7.2 M€.

Press release

1 2

S c r o l l

Products

.01

Pipeline

4 products in clinical development

.02

VALEDIA® – Prediabetes

Prediabetes
• Reduction of the risk of type 2 diabetes
• Positive Phase IIA clinical study

.03

LpD64

Overweight and /or obesity
• Modulation of intestinal microbiota
• Clinical Phase I/II positive

.04

VAL-070

Mild to moderate hypercholesterolemia
• Reduction of blood LDL-cholesterol
• Clinical Phase I/II positive

.05

TOTUM-63 – Non-alcoholic hepatic steatosis

Non-alcoholic hepatic steatosis
• Reduction of steatosis, risk factor for NASH
• Clinical Phase I/II positive

.06

TOTUM-63 – Arterial hypertension

Arterial hypertension
- Reduces hypertension, a risk factor for cardiovascular diseases
- Positive Phase IIA clinical study

Key figures

Patent families filed

4

All exploitation rights obtained

Employees

> 35

75% in R&D

Listed on the Stock Exchange

2017

Euronext Growth

Our last posts

16.10.2019

French Society of Financial Analysts (SFAF)

En savoir plus

14.10.2019

European Large & Midcap Event

En savoir plus

16.09.2019

Annual Meeting of the European Association for the Study of Diabetes (EASD)

En savoir plus

10.09.2019

Seminar Biotech Portzamparc

En savoir plus

Voir tous

VALBIOTIS© listed on the Stock Exchange

Investors

Follow us!